Patricia Inacio, PhD, science writer —

Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.

Articles by Patricia Inacio

Immunosuppressive Therapy Tied to More COVID-19 Hospitalization Risk

People with myasthenia gravis (MG) who are receiving immunosuppressive therapy are more likely to be hospitalized for a COVID-19 infection, yet the majority of patients are discharged without any complications, a single center study reports. “Immunosuppressive therapy was continued during COVID-19 infection,” and “most of hospitalized patients were discharged…

Onset of MG Following Sinopharm’s COVID-19 Vaccine Reported

Researchers in Iran reported the first case of myasthenia gravis (MG) following a Sinopharm vaccination against SARS-CoV-2, the virus that causes COVID-19. The report follows evidence of a possible link between COVID-19 vaccination and MG. While the mechanisms remain unclear, “if muscle weakness, ocular and bulbar [neck and facial]…

3 Cases of MG Possibly Caused by COVID-19 Vaccination: Report

Researchers in Italy have reported three cases of myasthenia gravis (MG) they say may possibly have been caused by a vaccine against SARS-CoV-2, the virus that causes COVID-19. “Clinicians should be aware of possible new-onset MG after SARS-CoV-2 vaccination, especially with the current recommendation of booster doses,” the team…

High-intensity Rehab in Hospital Linked to Delayed Recovery in Study

Contrary to increasing evidence, high-intensity inpatient rehabilitation was not found, in a Japanese study, to speed the recovery of people with myasthenia gravis (MG) who were intubated after a myasthenic crisis. Instead, according to researchers, “high-intensity rehabilitation was associated with delayed recovery in the ADL [activities of daily living],”…

Soliris Is Safe and Effective in Real-world Use, Small US Study Shows

Soliris (eculizumab) safely and rapidly led to clinical benefits in people with generalized myasthenia gravis (gMG) who are anti-acetylcholine receptor antibody positive, according to data from a small real-world U.S. study. Moreover, most patients discontinued maintenance immunomodulatory treatment. The study, “Safety and outcomes of eculizumab for acetylcholine…

MG Symptoms Weigh on Life Quality, Particularly for Women

People with myasthenia gravis, particularly women, have a high symptom burden that considerably affects their health-related quality of life, but the disease’s human cost is rarely given adequate study, a systematic literature review has found. Symptoms generally eased following treatment and disease remission. Still, there is…